Biodegradation of the Antiretroviral Tenofovir Disoproxil by a Cyanobacteria/Bacterial Culture

被引:1
|
作者
Silva, Sandra Regina [1 ]
Souza-Silva, Gabriel [1 ]
Moreira, Carolina Paula de Souza [2 ]
Vasconcelos, Olivia Maria de Sousa Ribeiro [2 ]
Silveira, Micheline Rosa [1 ]
Barbosa, Francisco Antonio Rodrigues [1 ]
Magalhaes, Sergia Maria Starling [1 ]
Mol, Marcos Paulo Gomes [2 ]
机构
[1] Univ Fed Minas Gerais, Fac Farm, BR-30510010 Belo Horizonte, Brazil
[2] Fundacao Ezequiel Dias, Dept Pesquisa & Desenvolvimento, BR-30510010 Belo Horizonte, Brazil
关键词
drug; <italic>Microcystis novacekii</italic>; <italic>Pseudomonas pseudoalcaligenes</italic>; by-products; tenofovir isoproxil monoester; WASTE-WATER; SURFACE-WATER; CYANOBACTERIUM; ALGAL; PHARMACEUTICALS; MICROALGAE; FUMARATE; ADAPTATION; STABILITY; RESIDUES;
D O I
10.3390/toxics12100729
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug extensively used by people living with HIV. The TDF molecule is hydrolysed in vivo and liberates tenofovir, the active part of the molecule. Tenofovir is a very stable drug and the discharge of its residues into the environment can potentially lead to risk for aquatic species. This study evaluated the TDF biodegradation and removal by cultures of Microcystis novacekii with the bacteria Pseudomonas pseudoalcaligenes. Concentrations of TDF of 12.5, 25.0, and 50.0 mg/L were used in this study. The process occurred in two stages. In the first 72 h, TDF was de-esterified, forming the tenofovir monoester intermediate by abiotic and enzymatic processes associated in an extracellular medium. In a second step, the monoester was removed from the culture medium by intracellular processes. The tenofovir or other by-products of TDF were not observed in the test conditions. At the end of the experiment, 88.7 to 94.1% of TDF and its monoester derivative were removed from the culture medium over 16 days. This process showed higher efficiency of TDF removal at the concentration of 25 mg/L. Tenofovir isoproxil monoester has partial antiviral activity and has shown to be persistent, maintaining a residual concentration after 16 days in the culture medium, therefore indicating the need to continue research on methods for total removal of this product from the aquatic environment.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Emtricitabine/Tenofovir Disoproxil Fumarate
    Toni M. Dando
    Antona J. Wagstaff
    Drugs, 2004, 64 : 2075 - 2082
  • [23] The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis
    Wang, Huilian
    Lu, Xi
    Yang, Xudong
    Xu, Nan
    MEDICINE, 2016, 95 (41)
  • [25] Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
    Yee, Ka Lai
    DiBenedetto, Adrienne
    Fan, Li
    Khalilieh, Sauzanne
    Triantafyllou, Ilias
    Vallee, Marie-Helene
    Fackler, Paul
    Stoch, S. Aubrey
    Iwamoto, Marian
    AAPS PHARMSCITECH, 2020, 21 (03)
  • [26] Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate
    Ka Lai Yee
    Adrienne DiBenedetto
    Li Fan
    Sauzanne Khalilieh
    Ilias Triantafyllou
    Marie-Helene Vallee
    Paul Fackler
    S. Aubrey Stoch
    Marian Iwamoto
    AAPS PharmSciTech, 21
  • [27] Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection
    Hazra, R
    Gafni, RI
    Maldarelli, F
    Balis, FM
    Tullio, AN
    DeCarlo, E
    Worrell, CJ
    Steinberg, SM
    Flaherty, J
    Yale, K
    Kearney, BP
    Zeichner, SL
    PEDIATRICS, 2005, 116 (06) : E846 - E854
  • [28] Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir
    Gerard, Laurence
    Chazallon, Corine
    Taburet, Anne-Marie
    Girard, Pierre-Marie
    Aboulker, Jean-Pierre
    Piketty, Christophe
    ANTIVIRAL THERAPY, 2007, 12 (01) : 31 - 39
  • [29] Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients
    Miller, MD
    Margot, N
    Lu, B
    Zhong, LJ
    Chen, SS
    Cheng, A
    Wulfsohn, M
    JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (05): : 837 - 846
  • [30] Renal outcomes with efavirenz plus tenofovir disoproxil fumarate/emtricitabine versus other tenofovir disoproxil fumarate-containing antiretroviral regimens among HIV-infected veterans: a national study
    LaFleur, J.
    Bress, A.
    Esker, S.
    Crook, J.
    Nyman, H.
    Bedimo, R.
    Tebas, P.
    Rosenblatt, L.
    ANTIVIRAL THERAPY, 2016, 21 : A60 - A60